ERAS Erasca, Inc.
USHealthcareAs of 2026-07-08 12:06
Why ERAS matters now
Erasca, Inc. (ERAS) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.32 with -0.24% on the session and $5.70B in market capitalization; recent performance reads 1-month +32.46% and YTD +267.47%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-183.4M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.1%.
The latest indexable market news headline is "DEADLINE ALERT for ERAS, NNOX, MSFT, BRCB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $14.00; recent insider activity includes Garner Ebun filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.57
P/S
0.00
EV/EBITDA
-15.70
DCF Value
$0.10
FCF Yield
-2.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-77.0%
ROA
-60.1%
ROIC
-32.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-183.4M | $-0.60 |
| Q4 2025 | $0.00 | $-29.1M | $-0.10 |
| FY 2025 | $0.00 | $-124.5M | $-0.44 |
| Q3 2025 | $0.00 | $-30.6M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.50
Target (Median)
$14.00
Target Range
$10.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.73
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.